Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2022.114685
Abstract: ONC206 is an imipridone derivative that is being developed clinically as a single agent given orally in a first-in-human trial (NCT04541082). This ongoing clinical trial requires pharmacokinetic analysis of ONC206 to fully characterize its pharmacologic… read more here.
Keywords: imipridone; onc206 human; quantitation; human plasma ... See more keywords
Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses
Sign Up to like & getrecommendations! Published in 2018 at "Biomarkers"
DOI: 10.1158/1535-7163.targ-17-a060
Abstract: Background: ONC201, an imipridone that is a selective antagonist of the G protein-coupled receptors dopamine receptor D2 (DRD2) and D3 (DRD3), has exhibited biologic activity and an exceptional safety profile in a phase II study… read more here.
Keywords: imipridone; glioblastoma; cancer; drd2 ... See more keywords
Abstract 3245: Preclinical evaluation of the imipridone family of small molecules, including analogues of clinical-stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3245
Abstract: We previously identified a novel, potent anti-cancer small molecule ONC201, which upregulates the integrated stress response (ISR) through ATF4/CHOP/DR5 and acts as a dual inactivator of Akt and ERK, leading to TRAIL gene activation. After… read more here.
Keywords: imipridone; onc201; potent anti; family ... See more keywords
Synthesis and Antiproliferative Activity of Novel Imipridone–Ferrocene Hybrids with Triazole and Alkyne Linkers
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15040468
Abstract: Imipridones, including ONC201, ONC206 and ONC212 (which are emblematic members of this class of compounds developed by Oncoceutics) constitute a novel class of anticancer agents, with promising results in clinical trials. With the aim of… read more here.
Keywords: cell; activity novel; synthesis antiproliferative; antiproliferative activity ... See more keywords